XML 75 R61.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Collaborative and Other Relationships (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Nov. 03, 2023
USD ($)
payment
Nov. 05, 2019
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Nov. 30, 2023
Collaborative and Other Relationships [Line Items]              
Revenues     $ 109,332 $ 82,491 $ 202,093 $ 151,269  
Torii Pharmaceutical Co.              
Collaborative and Other Relationships [Line Items]              
Revenues   $ 22,000          
Potential milestone payments receivable if regulatory approval before specified date   $ 15,000          
Maximum customary reduction on royalty rate   50.00%          
Torii Pharmaceutical Co. | Minimum              
Collaborative and Other Relationships [Line Items]              
Royalty rate if maintains sakigake designation   20.00%          
Royalty rate             20.00%
Torii Pharmaceutical Co. | Maximum              
Collaborative and Other Relationships [Line Items]              
Royalty rate if maintains sakigake designation   40.00%          
Royalty rate             80.00%
Clearside Biomedical, Inc.              
Collaborative and Other Relationships [Line Items]              
Upfront payment $ 5,000            
Number of milestone payments | payment 3            
Number of royalties tiers | payment 3            
Clearside Biomedical, Inc. | Annual Net Sales Of $2 Million              
Collaborative and Other Relationships [Line Items]              
Annual global net sales $ 2,000,000            
Clearside Biomedical, Inc. | Annual Net Sales Greater Than $1.5 Million              
Collaborative and Other Relationships [Line Items]              
Annual global net sales 1,500,000            
Clearside Biomedical, Inc. | Maximum              
Collaborative and Other Relationships [Line Items]              
Potential milestone payment 30,000            
Potential payment if milestone reached $ 47,500